0,5 - 0,2 IU/Kg
50% of TDD morning time
50% of TDD evening time
Titrate as per the Fasting and Postprandial
Begin with 4 IU and titrate by 2 units every 3 days
Titrate according to Postprandial Blood Glucose
0,1 IU/Kg in case of <8% Hba (1c)
0,3 IU/Kg in case of >8% HbA (1c)
Titrate according to the Fasting Blood Glucose (2 units every 3 days)
Production of insulin for people
with diabetes in Andijan
"Zamin Bio Health" is a leading insulin manufacturer providing people across the country with vital drugs. Our mission is to support the health and quality of life of patients with diabetes by providing effective and affordable solutions.
Our key features:
Innovative technologies - We use advanced methods and equipment to produce high-quality insulin.
Quality and safety - Strict quality control at all stages of production, compliance with international standards.
Availability of drugs - We ensure wide distribution of products throughout the country, making insulin available to everyone who needs it.
"Zamin Bio Health" is ready to be your reliable partner in the field of healthcare, providing stability and confidence in the future. Contact us for more information and cooperation.
Dosing is individual and determined in accordance with the needs of the patient. The physician determines whether one or several daily injections are necessary. NPH may be used alone or mixed with fast-acting insulin. In intensive insulin therapy the suspension may be used as basal insulin (evening and/or morning injection) with fast-acting insulin given at meals. Blood glucose monitoring is recommended to achieve optimal glycaemic control. The individual insulin requirement is usually between 0.3 and 1.0 international unit/kg/day.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness. Jusline is administered subcutaneously by injection in the abdominal wall, the thigh, the gluteal region or the deltoid region. Injection into a lifted skin fold minimizes the risk of unintended intramuscular injection. If necessary, Jusline R can be administered intravenously.
This should be carried out by healthcare professionals. Special warnings and precautions: Before travelling between different time zones, the patient should seek the doctor's advice since this may mean that the patient has to take the insulin and meals at different times. Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of Jusline.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Undesirable effects: Hypoglycemia, local allergy.
